Related Experiment Video

Updated: May 30, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263

Haikuo Tang1, Huanjie Shao, Chunrong Yu

  • 1Department of Oral and Maxicallifacial Surgery, The Affiliated Stomatology Hospital of Sun Yet-sen University, Guangzhou, Guangdong 510055, China.

Biochemical Pharmacology
|July 26, 2011
PubMed

Insights

YM155 suppresses Mcl-1 at the transcriptional level, enhancing cancer cell death. This survivin-independent mechanism, involving Mcl-1 downregulation, offers a new strategy for cancer treatment when combined with ABT-263.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • YM155 is a survivin suppressant with demonstrated anti-tumor effects.
  • The precise mechanism of YM155's action is not fully understood.
  • Understanding YM155's molecular targets is crucial for optimizing cancer therapy.

Purpose of the Study:

  • To elucidate the mechanism of YM155's anti-tumor activity.
  • To investigate the effects of YM155 on Bcl-2 family members.
  • To determine the role of Mcl-1 downregulation in YM155-induced cytotoxicity.

Main Methods:

  • Administered YM155 to various cancer cell lines.
  • Analyzed the impact of YM155 on Bcl-2 family member expression.
  • Performed Mcl-1 or survivin knockdown experiments.
  • Assessed the combined effects of YM155 and ABT-263.

Main Results:

  • YM155 significantly downregulates Mcl-1 transcriptionally across diverse cancer cell lines.
  • Mcl-1 suppression by YM155 is independent of survivin modulation and caspase activity.
  • Knockdown of Mcl-1 sensitizes cancer cells to YM155-induced cytotoxicity.
  • YM155 potentiates ABT-263-induced cell death by downregulating Mcl-1.

Conclusions:

  • Survivin-independent Mcl-1 suppression is a key mechanism in YM155's anti-tumor effects.
  • Targeting Mcl-1 with YM155 represents a novel therapeutic strategy.
  • Combination therapy with YM155 and ABT-263 shows promise for cancer treatment.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...